RRML - Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- June 2024 -
 
The evaluation of a diagnostic... 10
A comprehensive review of Prof... 9
Assessment of ocrelizumab impa... 7
Romanian Review of Laboratory ... 6
Monitoring the sensitivity of ... 6
Challenges in prophylactic the... 6
Diagnostic value of stress myo... 6
Effect of Systemic Inflammator... 5
Evaluation of routine laborato... 4
The role of nitro oxidative fa... 4

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Ahead of print DOI:10.2478/rrlm-2024-0019
XML
TXT

Research article

Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients

Smaranda Maier, Adina Huțanu, Laura Bărcuțean, Emanuela Sărmășan, Rodica Bălașa

Correspondence should be addressed to: Adina Huțanu

Abstract:

Background: Multiple sclerosis (MS) is a debilitating neurological disease characterized by inflammation, demyelination, and neurodegeneration in the central nervous system. Despite extensive research, the pathology of MS remains incompletely understood. Ocrelizumab (OCRE), a monoclonal antibody targeting CD20-positive B cells, has shown efficacy in relapsing (RR) and primary progressive (PP) MS. Neurofilaments (Nf) are emerging biomarkers of neuroaxonal injury, reflecting disease activity and treatment response in MS. This study aimed to assess the impact of OCRE on serum Nf levels (NfLs) in RRMS and PPMS patients and explore factors influencing treatment response. Methods: A prospective study included 23 RRMS and PPMS patients initiating OCRE and 23 healthy controls. Serum NfLs were quantified using ELISA. Statistical analyses evaluated changes in NfLs and factors influencing treatment response. Results: MS patients exhibited significantly higher NfLs than controls. OCRE treatment led to a significant reduction in NfLs after one cycle. Age and gender influenced treatment response, with older patients and females experiencing greater NfL reduction. Disability level and disease duration did not significantly affect NfLs reduction. Both RRMS and PPMS patients showed decreased NfLs levels with OCRE treatment. Conclusions: In conclusion, OCRE demonstrated efficacy in reducing NfLs levels in RRMS and PPMS patients after one cycle, with potential age and gender-related variations in treatment response. Larger longitudinal studies are needed to further elucidate OCRE’s mechanisms and implications for personalized MS treatment.

Keywords: neurofilament light chain, ocrelizumab, primary progressive multiple sclerosis, relapsing-remitting multiple sclerosis

Received: 11.4.2024
Accepted: 23.4.2024
Published: 29.5.2024

 
  PDF Download full text PDF
(1150 KB)